NewCelX Ltd. (NCEL) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$2.90

From 52W high−84.44%

Volume5520.00

Market cap$15.19M

P/E (TTM)8.0x

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$2.90

From 52W high

−84.44%

Volume

5520.00

Market cap

$15.19M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−3.9x

P/E (TTM)

8.0x

RSI (14)

40.4

MomentumView details →

1D Return

+5.20%

YTD Return

+39.47%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

8.0x

EV/EBITDA

−3.9x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

2.5x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

23.93%

ROA (TTM)

14.90%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+100.90%

FCF YoY

+40.31%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+91.79%

EBITDA YoY

−0.76%

MomentumView details →

1D Return

+5.20%

YTD Return

+39.47%

1Y Return

−84.32%

RSI (14)

40.4

vs 50D SMA

−15.76%

vs 200D SMA

−14.14%

Capital & dividendView details →

Debt/Equity

0.06x

Current Ratio

0.32x

Quick Ratio

0.32x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.53

EPS Surprise

0.00%

Beats (12Q)

4/12

Next Q EPS Est

−$0.65

Avg Surprise (4Q)

73.48%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−720101.00

Op. CF (TTM)

−7.69M

Next earningsMar 3, 2027 →

Latest newsMore news →

NewcelX priced a $1.4 million private equity financing at a 20% premium to support its lead Type 1 Diabetes program.81d ago

Similar companies

Dyadic International, Inc.DYAI Hoth Therapeutics, Inc.HOTH Estrella Immunopharma, Inc.ESLA Psyence Biomedical Ltd.PBM Jasper Therapeutics, Inc.JSPR TScan Therapeutics, Inc.TCRX Find similar companies →

Latest newsMore news →

NewcelX priced a $1.4 million private equity financing at a 20% premium to support its lead Type 1 Diabetes program.81d ago